Outcome of "indefinite for dysplasia" in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer.
暂无分享,去创建一个
[1] D. Rubin,et al. Outcome after surveillance of low‐grade and indefinite dysplasia in patients with ulcerative colitis , 2010, Inflammatory bowel diseases.
[2] R. McLeod,et al. Position Statement on the Diagnosis and Management of olorectal Neoplasia in Inflammatory Bowel Disease , 2022 .
[3] D. Faigel,et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. , 2006, Gastrointestinal endoscopy.
[4] Noam Harpaz,et al. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. , 2004, Gastroenterology.
[5] Alastair Forbes,et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.
[6] Noam Harpaz,et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. , 2003, Gastroenterology.
[7] K Abrams,et al. Inter‐observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis , 2001, The Journal of pathology.
[8] J. Satsangi,et al. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? , 2001, Gut.
[9] K. Abrams,et al. Colorectal cancer prevention in ulcerative colitis: a case‐control study , 2000, Alimentary pharmacology & therapeutics.
[10] A. Ekbom,et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study , 1998, Gut.
[11] G. Papatheodoridis,et al. Indefinite Dysplasia in Ulcerative Colitis Has Little Clinical Significance and Is Not Associated With p53 Protein Accumulation , 1998, American Journal of Gastroenterology.
[12] D. Sachar,et al. Cancer in Crohn's disease: dispelling the myths. , 1994, Gut.
[13] C. Williams,et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. , 1994, Gastroenterology.
[14] P. Prior,et al. Crohn's disease and colorectal cancer. , 1994, Gut.
[15] Brian H. Mayall,et al. Guidelines for implementation of clinical DNA cytometry , 1993 .
[16] M. Kimmey,et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. , 1992, Gastroenterology.
[17] P. Rabinovitch,et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. , 1992, Gastroenterology.
[18] T. Caspersson,et al. Comparative DNA analyses in longstanding ulcerative colitis with aneuploidy. , 1989, Gut.
[19] G. Roos,et al. DNA content and mucosal dysplasia in ulcerative colitis , 1989, Diseases of the colon and rectum.
[20] A. Price,et al. Observer variation in the assessment of dysplasia in ulcerative colitis , 1988, Histopathology.
[21] R. Löfberg,et al. Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development? , 1987, Gut.
[22] A. Öst,et al. Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study. , 1986, Gut.
[23] D. Ransohoff,et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.